Filter
1199
Filtered Results: 1199
Text search:
The
National
Institute
For
Communicable
Diseases,
South
Africa
Featured
Recommendations
105
New Publications
264
Language
Document type
No document type
597
Studies & Reports
296
Guidelines
139
Manuals
76
Strategic & Response Plan
36
Training Material
22
Fact sheets
14
Situation Updates
11
Resource Platforms
5
Infographics
2
Brochures
1
Countries / Regions
South Africa
87
Global
86
Africa
38
Kenya
37
Ethiopia
34
Nigeria
30
Uganda
27
Sierra Leone
26
Liberia
26
Rwanda
20
Ghana
18
India
16
Malawi
16
East and Southern Africa
16
Congo, Democratic Republic of
15
Bangladesh
15
Mozambique
15
Latin America and the Carribbean
14
Namibia
13
Western and Central Europe
13
Nepal
12
Tanzania
11
Lesotho
11
Asia
11
West and Central Africa
10
Zambia
9
South–East Asia Region
9
Guinea
8
Syria
8
Botswana
8
Senegal
7
Pakistan
7
South Sudan
7
Zimbabwe
6
Middle East and North Africa
6
Cambodia
5
Eswatini/ Swaziland
5
Brazil
5
Burkina Faso
4
Thailand
4
China
4
Myanmar / Burma
4
Yemen
4
Cameroon
3
Philippines
3
Somalia
3
Jordan
3
Afghanistan
3
Indonesia
3
Ukraine
3
Angola
3
Russia
3
Vietnam
3
Turkmenistan
3
Japan
3
Mauritius
3
Portugal
3
Spain
3
Mali
2
USA
2
Haiti
2
Germany
2
Central African Republic
2
Colombia
2
Sri Lanka
2
Western Pacific Region
2
Eastern Europe and Central Asia
2
Eastern Europe
2
Albania
2
Southern Africa
2
Moldova
2
Iran
2
United Kingdom
2
Guinea-Bissau
1
Morocco
1
Saudi Arabia
1
Togo
1
Iraq
1
Lebanon
1
Turkey
1
Gambia
1
Malaysia
1
Sudan
1
Argentina
1
Peru
1
North Macedonia
1
Serbia
1
Croatia
1
Ecuador
1
Greece
1
Italy
1
Canada
1
Tajikistan
1
Kyrgyzstan
1
Georgia
1
North America
1
France
1
Tunisia
1
Azerbaijan
1
Israel
1
Bosnia and Herzegovina
1
Authors & Publishers
Publication Years
Category
Countries
395
Public Health
137
Clinical Guidelines
108
Key Resources
50
Women & Child Health
49
Capacity Building
17
Pharmacy & Technologies
17
Toolboxes
COVID-19
99
HIV
84
TB
77
Mental Health
71
NCDs
69
Planetary Health
68
Rapid Response
60
AMR
50
Global Health Education
45
Disability
44
Ebola
32
NTDs
30
Caregiver
28
Health Financing Toolbox
20
Refugee
16
Pharmacy
13
Conflict
12
Natural Hazards
9
Zika
9
Polio
5
Specific Hazards
5
Social Ethics
4
Cholera
3
South Sudan
1
In 2012, all Member States of the World Health Organization (WHO) endorsed a historical target to reduce premature mortality from noncommunicable diseases
(NCD). This commitment was echoed in 2015 ...
In the context of the coronavirus disease (COVID-19) pandemic response, WHO identifies young people as a priority target audience with specific con...
SADC Communicable Disease Project
Component 5: Scaling-up Child and Adolescent HIV, TB and Malaria Continuum of Care and Support
DRAFT POST REGIONAL CONSENSUS AND VALIDATION MEETING Oct 2012
The document summarizes the infrastructure and activities for Ebola virus disease (EVD) prepared...
national programmes for occupational health and safety for health workers: lessons learned from countries: summary report of ... WHO online workshop, 15 July 2020
20 February 2013
Update on 2004 Background Paper (Written by Saloni Tanna)
Priority Medicines for Europe and the World "A Public Health Approach to Innovation"
This brief considers the rationale for shielding individuals at high risk of severe disease or death from COVID-19 in low- and middleincome countri...
The intent of these guidelines is to develop a holistic, coordinated, proactive and technology driven strategy for management of biological disasters through a culture of prevention, mitigation and ...
WHO published guidance for clinicians and health care decision-makers on the use of corticosteroids in patients with COVID-19.
We recommend systemic corticosteroids ... the treatment of patients with severe and critical COVID-19. We suggest not to use corticosteroids in the treatment of patients with non-severe COVID-19 as the treatment brought no benefits, and could even prove harmful. Treatment should be under supervision of a clinician.
Corticosteroids are listed in the WHO model list of essential medicines, readily available globally at a low cost. WHO encourages countries to maintain sufficient stocks of corticosteroids to treat COVID-19 and the other disease for which they are effective, while not maintaining excessive stocks which could deny other countries access.
The main objective of this mission was to assess the level of preparedness of Guinea-Bissau in respect of the WHO consolidated checklist. ... checklist helps countries to assess and test their level of readiness it is being used to identify concrete action to be taken and where countries will require support from partners. It lists 10 key components and tasks for both countries and the international community that should be completed within 30, 60 and 90 days from the date of issue of the list, with minimal requirements for equipment, material and human resources.
The components include: overall coordination; rapid response teams; public awareness and community engagement; infection prevention and control; epidemiological and laboratory surveillance; contact tracing; points of entry; laboratory; social mobilization and risk communication; budget.
The substantial burden of death and disability that results from interpersonal violence, road traffic injuries, unintentional injuries, occupational health risks, air pollution, climate change, and inadequate water and sanitation falls disproportion...
The report summarizes the estimates of the burden of disease attributable to unsafe drinking wat...
Internally displaced children are twice invisible in global and national data. First, because internally displaced people (IDPs) of all ages are often unaccounted for. Second, because age-disaggrega...
Little is known about the patterns of development assistance (DA) for each component of reproductive, maternal, newborn, child and adolescent health (RMNCAH) in conflict-affected countries nor about...
This document is a guide defining requirements for quality and safety for malaria rapid diagnostic testing services to safeguard the quality of ... results, the safety of the operators and patients and that of the environment for use by national malaria control programmes, regulators, implementers and rapid diagnostic providers.
Antimicrobial resistance has become a serious public health threat for effective treatment of an ever increasing range of infections caused by bacteria, parasites, viruses and fungi. When infections can no longer be treated by first-line antibiotics...
- Module 1: Understanding modelling approaches for sexual, reproductive, maternal, newborn, child and adolescent health, and nutrition
Coronavirus disease 2019 (COVID-19) has a wide range of docume...
5 May 2021
This Information Note is intended to assist national TB programmes and health personnel worldwide to maintain essential tuberculosis (TB) services during the COVID-19 pandemic and in ... recovery phase. It is important that recent progress made in TB prevention and care is not reversed by COVID-19. The WHO Global TB Programme, along with WHO regional and country offices, developed this note in response to questions received from Member States and other partners since the start of the pandemic. The note includes references to other published WHO information products relevant to TB practitioners. WHO continues to monitor the situation closely for any changes that may influence this note and will issue updates should any factors change.
These guidelines provide a framework for effective action to facilitate access to safe and ethical
testing services for different population groups. The<...
Access to NCD medicines: emergent issues during the COVID-19 pandemic and key structural factors
recommended
The coronavirus disease (COVID-19) pandemic exacerbated pre-existing inequalities in the treatment and care of noncommunicable ... (NCDs). This report examines the effect of the COVID-19 pandemic on access to NCD medicines, and the policies and strategies implemented by countries and health systems to anticipate and mitigate stresses across NCD medicine supply chains. The full range of upstream and downstream impacts are investigated, including: manufacturing; procurement, importation and last mile delivery; patient-level effects through affordability and availability; and the effects on NCD medicine availability by category of disease. The report culminates in recommended actions and interventions for key stakeholders in the NCD pharmaceutical supply chain, including governments, regulatory authorities, manufacturers and the private sector; as well as directions for future research for improving access and supply chain access resilience.
